Share Print

FDA Withdraws Approval of Avastin for Breast Cancer


Dec. 17, 2010 – The FDA has made the recommendation that provisional approval for treating metastatic breast cancer with the drug Avastin be withdrawn. In this Cancer Connection podcast, Siteman Cancer Center medical oncologist Michael Naughton, MD, talks about the recommendation and how it will affect patients. According to Naughton, some of the side effects from Avastin can be potentially dangerous, but he says the drug has helped many women. Naughton says the FDA's ruling is disappointing and that women who have been prescribed Avastin and are seeing benefits from the drug should continue using it.

Related Content: